Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough-Therapy Designation for the Treatment of PROC

PR NewswireMarch 18, 2025

Tag: Alphamab , JSKN003 , PROC , ADC

PharmaSources Customer Service